PD166793 hydrate

• Catalog No.: P0047
• M. F.: C17H20BrNO5S
• M. W.: 430.3134
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: (2S)-2-[4-(4-bromophenyl)benzenesulfonamido]-3-methylbutanoic acid hydrate
• IUPAC Traditional name: (2S)-2-[4-(4-bromophenyl)benzenesulfonamido]-3-methylbutanoic acid hydrate
• Synonyms: (S)-2-(4′-Bromo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid hydrate

DATABASE IDS

• MDL Number: MFCD12912437

PROPERTIES

• Empirical Formula (Hill Notation): C17H18BrNO4S · xH2O
• Purity: ≥98% (HPLC)
• Apperance: solid
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Temperature: 2-8°C
• German water hazard class: 2

DETAILS

Description (English)

Biochem/physiol Actions
PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). Adding PD166793 to the high-fat diet substantially reduced the rise in blood glucose. The improvement of glucose homeostasis in PD166793-treated ZDF rats was a result of the enhancement of β-cell function. It prevents β-cell dysfunction and diabetes in female ZDF rats on a high-fat diet. It has been shown to block left ventricular remodeling and dysfunction in a rat model of heart failure. Preservation of normoglycemia and normal glucose tolerance in compound PD166793-treated animals is accompanied by preservation of the high serum insulin levels that are a consequence of the insulin resistance present in these animals. It is not reversing insulin resistance these animals. The most striking effect of the compound is on pancreatic insulin content and β-cell volume.

Description (简体中文)

Biochem/physiol Actions
PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). Adding PD166793 to the high-fat diet substantially reduced the rise in blood glucose. The improvement of glucose homeostasis in PD166793-treated ZDF rats was a result of the enhancement of β-cell function. It prevents β-cell dysfunction and diabetes in female ZDF rats on a high-fat diet. It has been shown to block left ventricular remodeling and dysfunction in a rat model of heart failure. Preservation of normoglycemia and normal glucose tolerance in compound PD166793-treated animals is accompanied by preservation of the high serum insulin levels that are a consequence of the insulin resistance present in these animals. It is not reversing insulin resistance these animals. The most striking effect of the compound is on pancreatic insulin content and β-cell volume.